Thailand Cannabis & Hemp Market Intelligence
Thai cannabis, hemp post-2022 legalisation, 2024 re-regulation. Medical CBD, wellness, food-beverage infusion, hemp industrial; regulatory flux binding variable.
Key takeaways
- 1
Thailand's cannabis, hemp trajectory: medical legalisation 2018 β recreational decriminalisation 2022 (first in Asia) β re-regulation under cannabis bill 2024-2025 restricting lifestyle/recreational to prescription, medical-grade only. Market is in active policy flux.
- 2
Market segments: medical cannabis, CBD wellness (~, FDA-licensed), food/beverage CBD infusion (~), hemp fibre, seed industrial (~), recreational/lifestyle under new regulation (~), R&D, pharma cannabinoid (~).
- 3
Regulators: FDA Narcotics Division (medical licence, prescription), MOPH (clinic approval, pharmacist dispensing), MOAC Department of Agriculture (cultivation licensing), MOI (industrial hemp).
- 4
Operator landscape: no major listed pure-play; small-cap JVs (RS Group's RSX Cannabis historical, MEGA Lifesciences pharma CBD research). Private operators dominate: Golden Triangle Group, Mangosteen Valley, smaller clinics, dispensaries. Cannabis cooperative model important for rural farmers.
- 5
Binding variable: re-regulation trajectory β more restrictive framework caps lifestyle, beverage segments but preserves medical, hemp industrial. Export market (hemp fibre, CBD isolate) is bright spot.
Executive summary
Thailand's cannabis, hemp sector is in policy flux. Medical cannabis was legalised in 2018, recreational cannabis decriminalised in June 2022 (first Asian country to do so), and the Anutin Charnvirakul-led Bhumjaithai Party cannabis policy peaked with thousands of dispensaries opening 2022-2023. Post-2023 elections, change of government, re-regulation under the Cannabis Act 2024-2025 has restricted lifestyle/recreational use β cannabis is now prescription-only for medical use under FDA Narcotics oversight; dispensaries must transition to licensed pharmacies or close.[, ]
Market segments: medical cannabis, CBD wellness (~ β FDA-licensed clinics, pharmacy dispensing; growing under new regulation). Food/beverage CBD infusion (~ β ICHI CBD beverages, other F&B). Hemp fibre, seed industrial (~ β MOI-licensed, textile, construction, skincare ingredients). Recreational/lifestyle (~ β under restriction; contracting). R&D, pharma cannabinoid (~ β academic, pharmaceutical research).[, ]
Operator landscape: no major Thai listed pure-play cannabis company; small-cap JVs, research partnerships existed (RS Group's historical RSX Cannabis JV now wound down, MEGA Lifesciences pharma-grade CBD research, manufacturing). Private operators dominate: Golden Triangle Group (medical), Mangosteen Valley (wellness), smaller cooperative-model cultivation for rural farmers. Cannabis cooperative, community-level licensing was centrepiece of 2022 policy, retained in medical pathway post-re-regulation.[, ]
Policy, market sentiment index (directional, 2018-2024)
2018
Market sentiment
20
Context
Medical legalisation begins
2020
Market sentiment
35
Context
Medical framework expands, first clinics
2022
Market sentiment
70
Context
Recreational decriminalisation peak; dispensary boom
2023
Market sentiment
60
Context
Peak operator count; political uncertainty
2024
Market sentiment
45
Context
Re-regulation restricts lifestyle; medical pathway preserved
| Year | Market sentiment | Context |
|---|---|---|
| 2018 | 20 | Medical legalisation begins |
| 2020 | 35 | Medical framework expands, first clinics |
| 2022 | 70 | Recreational decriminalisation peak; dispensary boom |
| 2023 | 60 | Peak operator count; political uncertainty |
| 2024 | 45 | Re-regulation restricts lifestyle; medical pathway preserved |
Cannabis, hemp segment mix (% of FY2024 revenue)
Medical cannabis, CBD wellness
Share %
Notes
FDA-licensed; growing
Hemp fibre, seed industrial
Share %
Notes
MOI-licensed; export
Recreational/lifestyle (regulated)
Share %
Notes
Under re-regulation; contracting
R&D, pharma cannabinoid
Share %
Notes
Academic, pharma research
| Segment | Share % | Notes |
|---|---|---|
| Medical cannabis, CBD wellness | 35% | FDA-licensed; growing |
| Food, beverage CBD infusion | 20% | ICHI, F&B brand; under restriction |
| Hemp fibre, seed industrial | 20% | MOI-licensed; export |
| Recreational/lifestyle (regulated) | 15% | Under re-regulation; contracting |
| R&D, pharma cannabinoid | 10% | Academic, pharma research |
Analyst framing
Why this report
Unlock the full report
Need more than the web report? Ask for a scoped export or source appendix.
Every report keeps visible citations and source metadata. Terms.
Key figures
Selected anchors from the report evidence pack.
Thai medical cannabis licensed clinics (2024)
Thai Food and Drug Administration, Department of Thai Traditional and Alternative Medicine
Thai cannabis and hemp market size estimate (2024)
Kasikorn Research Centre, Thai FDA regulatory filings, Bangkok Post sector analysis
Thai industrial hemp THC threshold (regulatory)
Thai FDA Ministerial Notifications, Narcotic Plants Act, Department of Agriculture
Thai cannabis recriminalisation β legislative status (2024-2025)
Ministry of Public Health, Thai FDA, National Assembly legislative tracker
Thai CBD wellness product export potential estimate
DITP export promotion reports, Thai FDA CBD product registry, industry surveys
Related reports
Thailand Healthcare Services & Medical Tourism Market Intelligence
Thailand runs Asia's deepest medical-tourism franchise β 60+ JCI-accredited hospitals, ~3-4M medical-tourism visits generating USD 1.5-2B in receipts. BDMS (SET: BDMS) anchors at >THB 110B FY2024 across 50+ hospitals; Bumrungrad (SET: BH) runs >60% international-patient revenue mix. Public insurance (UCS ~47M, SSS ~15M) plus private, international cash-pay shape the payor mix. Physician supply at 0.9-1.0 per 1,000 is the binding workforce constraint on growth.
Open report β
Thailand Pharmaceuticals Market Intelligence
Thailand's pharmaceuticals market reached approximately THB 280B in FY2024, split roughly 75% imported (originators, generics) and 25% domestic (GPO state, listed, private generics). Government Pharmaceutical Organisation is the state anchor for essential medicines, ARV, biosimilar manufacturing. Mega Lifesciences (SET: MEGA) is the largest Thai-listed pharma (~THB 16B revenue). Multinational originator subsidiaries (GSK, Pfizer, Novartis, Roche) lead originator, specialty supply. UCS, SSS, CSMBS multi-payer framework, NLEM reimbursement drive price-competition dynamics.
Open report β
Thailand Beauty, Skincare Deep Dive
Deep-dive into Thai beauty, skincare retail market ~THB 90-110B FY2024. Categories: skincare ~42%, makeup, colour cosmetics ~26%, haircare ~16%, fragrance ~8%, body, bath ~8%. Brand mix: K-beauty (Innisfree, Laneige, AmorePacific, Sulwhasoo, Etude House) ~22%, J-beauty (Shiseido, SK-II, Hada Labo, Kose) ~14%, global Western (L'OrΓ©al, EstΓ©e Lauder, LVMH, P&G) ~32%, Thai brand, indie (Mistine, Oriental Princess, Snail8, Namu Life, Cute Press, Beauty Buffet, Eveandboy) ~22%, indie, niche ~10%. Channel: Watsons, Boots, Eveandboy, Beauty Buffet, Sephora, department, drug, Shopee, Lazada, TikTok Shop, brand D2C. KOL, Xiaohongshu emerging. Thai FDA, ASEAN Cosmetic Directive.
Open report β
Thailand Cigarette, Tobacco Export Deep Dive
Deep-dive into Thai cigarette, tobacco market ~THB 80-100B FY2024, ~25-30B sticks volume; declining structurally with public-health excise, smoke-free policy. Operators: TTM (Tobacco Authority of Thailand state monopoly under Excise Department) ~50-55% domestic share; Philip Morris Thailand (Marlboro, L&M, Chesterfield) ~22-28%; Japan Tobacco International (Camel, Mevius, Winston) ~18-22%; smaller foreign, smuggled grey market. Excise, Health Tax, Tobacco Control Act B.E. 2560, smoke-free zone, plain-packaging, e-cigarette, vape ban regulate. Thai tobacco leaf production ~30-50k tonne (Northeast, North) export. WHO FCTC compliance.
Open report β